Concepedia

Urvi Aras

UA

10

Publications

210

Citations

10

H-Index

2012

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Roswell Park Comprehensive Cancer Center

Urvi Aras is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, oncology, and pharmacotherapy.

Top concepts

Publications per year

2012–2023

10

Publications

10

<scp>First‐in‐human</scp> study of deucravacitinib: A selective, potent, allosteric <scp>small‐molecule</scp> inhibitor of tyrosine kinase 2

Ian M. Catlett, Urvi Aras, Lars Hansen et al. · Clinical and Translational Science · 2022 · 52 citations · Full text

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data

Gerald J. Fetterly, Urvi Aras, Patricia D. Meholick et al. · The Journal of Clinical Pharmacology · 2013 · 35 citations

Chemopreventive and anti‐angiogenic effects of dietary phenethyl isothiocyanate in an <i>N</i>‐methyl nitrosourea‐induced breast cancer animal model

Urvi Aras, Yash Gandhi, Patricia A. Masso‐Welch et al. · Biopharmaceutics & Drug Disposition · 2012 · 26 citations · Full text

SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2

Ian M. Catlett, Urvi Aras, Y Liu et al. · Annals of the Rheumatic Diseases · 2017 · 21 citations · Full text

Model‐Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors

Yue Zhao, Kinjal Sanghavi, Amit Roy et al. · Clinical Pharmacology & Therapeutics · 2023 · 15 citations · Full text

, , +19

Rows per page

1–5 of 10